News

Interim results from the first nine participants in a Phase 2 clinical trial testing Arcturus Therapeutics’ experimental inhaled therapy ARCT-032 in adults with cystic fibrosis (CF) are expected next month. The U.S.-based study, called LunairCF (NCT06747858), is still recruiting CF patients who aren’t eligible for CFTR…

A new noninvasive prenatal test for cystic fibrosis (CF) and three other inherited conditions, launched by Natera, uses a sample of the mother’s blood to screen fetal DNA. The test, called Fetal Focus, may be particularly useful when the baby’s biological father isn’t available for genetic testing to…

Persistent Pseudomonas aeruginosa infection in people with cystic fibrosis (CF) who have received treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) seems to be a main driver of lung inflammation, a new study found. Trikafta is a highly effective CFTR modulator. Researchers also observed an “all-or-none” pattern in infection clearance in most…

The U.S. Food and Drug Administration (FDA) has granted two new designations to CMTX-101, an antibody-based therapy Clarametyx Biosciences is developing to treat bacterial lung infections in people with cystic fibrosis (CF). The regulatory agency granted CMTX-101 fast track designation, which aims to speed the development of new…

Almost 30% of cystic fibrosis (CF) patients who had a lung transplant in the U.S. were prescribed Trikafta after surgery, a recent analysis shows. Sinus disease and low body mass index (BMI), a measure of body fat that takes into account weight and height, were associated with receiving…

Grants that provide financial assistance for nutrition may help people with cystic fibrosis (CF) maintain a healthy body weight, according to a study whose findings emphasize clinicians’ role in making sure patients know about the resources available to them. “The results of our study highlight the importance of active…

Men with cystic fibrosis (CF) are generally knowledgeable about how their disease affects fertility, but they still want to be able to talk about their reproductive options with their providers, who may be uncomfortable or unskilled with these discussions, particularly with teens.. The findings indicate a need for more…

Health Canada has approved the next-generation CFTR modulator therapy Alyftrek for people 6 years and older with cystic fibrosis (CF) who have at least one mutation that’s responsive to the therapy. That includes the most common CF-causing mutation, F508del. The approval in Canada follows similar approvals in…

All eligible cystic fibrosis (CF) patients in England can now receive Vertex Pharmaceuticals’ CF treatment Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), after the company reached a reimbursement agreement with the National Health Service (NHS). The decision follows a positive recommendation from the National Institute for Health and Care Excellence and the treatment’s…

The first participant has been dosed in a Phase 2b clinical trial testing BiomX’s experimental inhaled therapy BX004 in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa lung infection. “This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P.